Introduction
Sudden cardiac death (SCD) is a devasting event. In a prospective study [1] the addition of genetic testing to autopsy investigation found an annual incidence of SCD of 1.3 cases per 100 000 persons 1 to 35 years of age, 72% of the cases were boys or young men. At present approximately 30% of patients are genotype negative. A clinically relevant cardiac mutation was de tected in 27% o f cases and identified an inherited cardiac disease in 13% of the families in which unexp lained SCD occurred. The genetic defects that cause catecholaminergic polymorphic ventricular tachy cardia (CPVT) may be linked to mutations in chromo some 1 ( 115,700,007,768,781, r everse s trand GRCh38:
CM000663.2) [2] . Thus far, two genetic variants have been identified [3, 4] 
Treatment
Clinical therapy for CPVT traditionally has relied on re ducing precipitating circumstances (vigorous physical activity and high emotional stress must be avoided in those patients), h ighdose n oncardioselective βadrenergic blockade and adhesion to therapy [3, 4] . In addition to blunting w holebody adrenergic tone, Heart rate up to 170/min. 
